Pipeline — registered trials by phase
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
— · Type 1 Diabetes · Completed · est. 2020-09-29
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
— · Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus · Recruiting · est. 2027-02-22
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
— · Type 1 Diabetes Mellitus · Completed · est. 2022-01-17
Pivotal Omnipod Horizon™ Automated Glucose Control System
— · Type 1 Diabetes Mellitus · Completed · est. 2020-07-10
Simplified Onboarding in Adults With Type 2 Diabetes
— · Type 2 Diabetes Mellitus · Completed · est. 2026-01-06
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
— · Type 1 Diabetes · Recruiting · est. 2027-06
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
— · Diabetes Mellitus · Completed · est. 2024-01-31
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D
— · Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes (DM) · Recruiting · est. 2026-12-31
Omnipod 5 System Compared to Pump Therapy
— · Type 1 Diabetes · Completed · est. 2023-09-14
French Prospective Multicentric Study in Real World
— · Diabetes, Diabetes Mellitus, Type 1 Diabetes · Active Not Recruiting · est. 2027-07-30
SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes
— · Diabetes Mellitus · Completed · est. 2025-09-08
Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)
— · Type 1 Diabetes Mellitus · Completed · est. 2017-04-07
Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
— · Type 2 Diabetes Mellitus · Completed · est. 2022-03-06
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
— · Diabetes Mellitus, Type 1, Type 2 · Completed · est. 2025-11-10
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
— · Type 2 Diabetes Mellitus · Recruiting · est. 2026-12-24
Prepivotal Omnipod Horizon™ Automated Glucose Control System
— · Type 1 Diabetes Mellitus · Completed · est. 2020-01-31
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
— · Diabetes Mellitus, Type 1 · Completed · est. 2024-08-16
An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes
— · Type 2 Diabetes Mellitus · Completed · est. 2026-03-30
Insulet Artificial Pancreas Early Feasibility Study
— · Type 1 Diabetes · Completed · est. 2017-02
Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
— · Diabetes, Type 1 Diabetes, Diabetes Mellitus · Recruiting · est. 2027-11
Insulet Artificial Pancreas Free-Living IDE3
— · Type1 Diabetes Mellitus · Completed · est. 2019-05-28
OP5-005 Using Omnipod 5 in Adults With Type 2
— · Type2 Diabetes · Completed · est. 2024-03-01
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes
— · Diabetes Mellitus · Completed · est. 2026-05-06
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Insulet is lead sponsor; 23 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-21Current report (material event)
- 8-K2026-09-16Current report (material event)
- 8-K2026-09-10Current report (material event)
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-05Current report (material event)
- 8-K2026-06-25Current report (material event)
- SD2026-05-28SD
- 8-K2026-05-26Current report (material event)
- 8-K2026-05-21Current report (material event)
- SCHEDULE 13G/A2026-05-14SCHEDULE 13G/A
- 10-Q2026-05-06Quarterly report
- SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
- 8-K2026-05-06Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 8-K2026-04-29Current report (material event)
- DEFA14A2026-04-06DEFA14A
- DEF 14A2026-04-06Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- UPLOAD2026-03-24UPLOAD
- CORRESP2026-03-23CORRESP
- UPLOAD2026-03-17UPLOAD
- 8-K2026-03-12Current report (material event)
- 8-K2026-03-04Current report (material event)
- 8-K/A2026-02-24Current report (amended)
- 10-K2026-02-18Annual report
- 8-K2026-02-18Current report (material event)
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- 8-K2026-02-03Current report (material event)
- 8-K2025-12-19Current report (material event)
- 8-K2025-12-17Current report (material event)
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-06Current report (material event)
- SCHEDULE 13G/A2025-10-30SCHEDULE 13G/A
- 8-K2025-10-23Current report (material event)
- 8-K2025-09-16Current report (material event)
- SCHEDULE 13G/A2025-08-13SCHEDULE 13G/A
- 10-Q2025-08-07Quarterly report
- 8-K2025-08-07Current report (material event)
- 8-K2025-06-09Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.